News

Income investors have liked Pfizer (NYSE: PFE) for years. However, the big drugmaker's exceptionally juicy dividend these days has made its stock even more attractive.

But when a dividend yield

There are a few things that Ford Motor Company (NYSE: F), Target (NYSE: TGT), and Pfizer (NYSE: PFE), have in common. They are all components of the prestigious S&P 500. The stocks all pay a

The average stock on the S&P 500 yields just 1.4%. If you invested $54,000 into stocks averaging that kind of a yield, you'd collect just $756 in annual dividend income. But if you invested that

Buying a quality dividend stock near a multiyear low can be a great move, especially if you're willing to be patient and hang on for the long term. As long as the dividend remains intact, the yield

Entering trading on Monday, the S&P 500 has declined around 6% since the start of the year. And that's after recovering recently -- it was down much more than that in early April when global tariffs

The market for obesity drugs presents one of the most lucrative targets for biopharmaceutical companies. Eli Lilly and Novo Nordisk are already raking in billions of dollars in sales with their

Big pharmaceutical companies as well as smaller biotechs have been hoping to score a win in one of today's highest-growth treatment areas: and that's weight loss. Analysts forecast a compound annual

Few would dispute that Pfizer (NYSE: PFE) is an icon within the pharmaceutical world. And, giving credit where it's due, the drugmaker largely led the charge against the COVID-19 pandemic with both

Having significant capital in the bank when investing in equities is helpful, but is by no means necessary. Even with a relatively modest sum, like $30, it's possible to acquire one whole share of a

The anti-obesity drug market has the potential to be massive, with multiple analysts projecting it may reach at least $100 billion by 2030. As a result, many top healthcare companies are vying for a

Although it isn't the largest therapeutic area in the pharmaceutical industry, the market for weight loss therapies has caught fire in recent years. The leading medicines in this field include

What a difference five years can make. Just look at Eli Lilly (NYSE: LLY). In April 2020, the drugmaker stood in the shadows to some extent with companies including Johnson & Johnson, Pfizer, and

On Tuesday, investors continued to snap up shares of big pharmaceutical company Pfizer (NYSE: PFE). Somewhat counterintuitively, this week's rise came after the company announced it was ending the

Pfizer (NYSE: PFE) recently reminded investors how risky the drug-development business can be. On April 14, the company told investors it would scrap development of danuglipron, its oral GLP-1

Bad news for Pfizer (NYSE: PFE) turned into good news for Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), and Viking Therapeutics (NASDAQ: VKTX) Monday morning, each of which is rising on Pfizer's

Pfizer's (NYSE: PFE) shares have been southbound for the better part of three years, partly because it was unable to repeat its incredible financial performance during the early pandemic years

Roughly four out of five S&P 500 (SNPINDEX: ^GSPC) stocks are in negative territory in 2025. Most of those stocks weren't immune to the meltdown that occurred in recent days following President

If you're a dividend investor, now can be an ideal time to go bargain-hunting. The stock market is in the midst of a broad sell-off, with investors dumping all types of stocks, both bad ones and

Pharmaceutical giant Pfizer (NYSE: PFE) was a big winner during the COVID-19 pandemic. Its vaccine and antiviral pill generated billions of dollars in sales. However, that revenue source has largely

In 2020, many companies tried to develop effective coronavirus vaccines, but two ended up succeeding and dominating the field: Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA). These two vaccine makers

Pfizer's (NYSE: PFE) share price has fallen more than the S&P 500 so far this year. The big pharma stock is nearly 60% below its high set in late 2022. By most standards, Pfizer looks like the

Buying stock in great companies when they are dealing with some short-term issue that creates stock price weakness can set investors up for big gains down the road. As long as the business is still

Many investor eyes were on the pharmaceutical industry on Tuesday, and not necessarily for the right reasons. The Trump administration's promised tariffs were set to go into effect the following

Explore the exciting world of Pfizer (NYSE: PFE) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential

Healthcare stocks have been out of vogue with investors since late 2022. Myriad reasons underlie the negative sentiment toward the healthcare sector, but in some instances, this dour take isn't